| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2004-03-0848 |
| P8608 | Fatcat ID | release_my4aavw5y5hpdeogcgtlwkhrhm |
| P932 | PMC publication ID | 1895044 |
| P698 | PubMed publication ID | 15713796 |
| P5875 | ResearchGate publication ID | 8018933 |
| P2093 | author name string | Lixin Wang | |
| Ou Cao | |||
| Roland W Herzog | |||
| Alexander Schlachterman | |||
| Eric Dobrzynski | |||
| P2860 | cites work | Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors | Q24673796 |
| Tolerance, danger, and the extended family | Q29547532 | ||
| Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences | Q30657785 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells | Q33810726 | ||
| Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo | Q34040679 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| In vivo activation of antigen-specific CD4 T cells. | Q34178091 | ||
| Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer | Q34985105 | ||
| Adeno-associated virus vectors for therapeutic gene transfer | Q35052563 | ||
| Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 | ||
| Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus | Q36159178 | ||
| Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. | Q36438020 | ||
| Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 | ||
| Sustained correction of bleeding disorder in hemophilia B mice by gene therapy | Q36454880 | ||
| Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors | Q36734619 | ||
| Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors | Q39601191 | ||
| Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D | Q39881602 | ||
| AAV-mediated gene transfer to skeletal muscle. | Q40588802 | ||
| Optimized production of high-titer recombinant adeno-associated virus in roller bottles | Q40675191 | ||
| Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration | Q40940810 | ||
| Use of adoptive transfer of T-cell-antigen-receptor-transgenic T cell for the study of T-cell activation in vivo | Q41492218 | ||
| Posttranslational modifications of recombinant myotube-synthesized human factor IX. | Q43513933 | ||
| Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo | Q43687301 | ||
| AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. | Q44753961 | ||
| Update on gene therapy for hereditary hematological disorders | Q44804864 | ||
| Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors | Q45299117 | ||
| Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector | Q45598603 | ||
| Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques | Q45731350 | ||
| Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors | Q45735547 | ||
| Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors | Q45736630 | ||
| Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 | ||
| Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. | Q45869966 | ||
| Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer | Q45874902 | ||
| Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. | Q45875077 | ||
| Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation | Q45879591 | ||
| Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. | Q45879597 | ||
| Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors | Q45879602 | ||
| Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males | Q45881920 | ||
| Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy | Q45884700 | ||
| Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy | Q45888356 | ||
| Visualization of specific B and T lymphocyte interactions in the lymph node | Q47892330 | ||
| Cell-Associated Ovalbumin Is Cross-Presented Much More Efficiently than Soluble Ovalbumin In Vivo | Q57227930 | ||
| Cross-presentation: a general mechanism for CTL immunity and tolerance | Q57228022 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | local immune response | Q106596240 |
| P304 | page(s) | 4226-4234 | |
| P577 | publication date | 2005-02-15 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Systemic protein delivery by muscle-gene transfer is limited by a local immune response | |
| P478 | volume | 105 |
| Q34814931 | A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer |
| Q42690486 | A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque |
| Q45863500 | AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. |
| Q33659389 | AAV's anatomy: roadmap for optimizing vectors for translational success |
| Q91296268 | Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies |
| Q33799315 | Anti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection |
| Q45881605 | Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules |
| Q64977765 | Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. |
| Q39394803 | Complexity of immune responses to AAV transgene products - Example of factor IX. |
| Q43427810 | Direct comparison of four adeno-associated virus serotypes in mediating the production of antiangiogenic proteins in mouse muscle |
| Q40417058 | Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer. |
| Q52721830 | Gene Therapy With Regulatory T Cells: A Beneficial Alliance. |
| Q38937862 | Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease |
| Q28081911 | Gene therapy for hemophilia |
| Q33226431 | Identification of mouse AAV capsid-specific CD8+ T cell epitopes |
| Q38195598 | Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside |
| Q42183295 | Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX. |
| Q34263314 | Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cells |
| Q42024301 | Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. |
| Q39501844 | Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. |
| Q35451204 | Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. |
| Q41920883 | Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer |
| Q37939843 | Innate Immune Responses to AAV Vectors |
| Q42246858 | Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy |
| Q39639059 | Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle |
| Q37071092 | Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy |
| Q54612588 | Long-term persistence of hepatitis B surface antigen and antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice. |
| Q45883516 | Major role of local immune responses in antibody formation to factor IX in AAV gene transfer |
| Q44861538 | Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery |
| Q40055959 | Muscle Gene Therapy for Hemophilia. |
| Q36532822 | Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model |
| Q45871000 | Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. |
| Q36582796 | Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector |
| Q34574858 | Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells |
| Q38546492 | Recent advances in gene therapy for lysosomal storage disorders |
| Q40049410 | Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer |
| Q33690970 | Role of cyclic AMP-dependent kinase response element-binding protein in recombinant adeno-associated virus-mediated transduction of heart muscle cells |
| Q21245486 | Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B |
| Q54457954 | Safety and Efficacy of Regional Intravenous (RI) Versus Intramuscular (IM) Delivery of rAAV1 and rAAV8 to Nonhuman Primate Skeletal Muscle. |
| Q34025098 | Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. |
| Q45861904 | Soluble TNF-α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer |
| Q57039821 | Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy |
| Q42400718 | TLR3 signaling does not affect organ-specific immune responses to factor IX in AAV gene therapy |
| Q37814051 | The complex and evolving story of T cell activation to AAV vector-encoded transgene products |
| Q34517044 | Transduction of skeletal muscles with common reporter genes can promote muscle fiber degeneration and inflammation |
| Q44819846 | Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. |
| Q35561776 | Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer |
| Q42121728 | Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice |
Search more.